Evaluation of Herpes Zoster Characteristics and Costs in Cancer Population.

Launched by AC CAMARGO CANCER CENTER · Jan 5, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring how often cancer patients develop herpes zoster, commonly known as shingles, and the impact it has on their treatment and healthcare costs. Shingles can be especially serious for cancer patients, leading to delays in their cancer treatment, possible hospital stays, and increased risk of long-lasting pain called postherpetic neuralgia. The study aims to gather information on how many cancer patients experience shingles, how many need to be hospitalized, and the costs associated with these hospitalizations from different healthcare providers.

To be eligible for the study, participants must be cancer patients who visited the AC Camargo Cancer Center between September 2019 and August 2022 and had an acute episode of shingles or a recurrence of shingles. This includes individuals currently undergoing cancer treatment or those who have recently completed treatment. The information collected will help raise awareness about the importance of shingles vaccination for cancer patients. If you or a loved one meet these criteria, participating in this study could contribute valuable insights into managing shingles in the cancer population.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • -Admission at AC Camargo Cancer Center between 2019 september and 2022 august at emergency department and/or inpatient ward, including intensive care unit
• • Acute episode of Herpes Zoster or recurrence (see item 5.1. for ICD-10 codes).
• • Acute episode of HZ is clinically defined as painful, polymorphic, acute cutaneous lesions composed of macules, papules, vesicles and crusts at different stages of development, affecting delimited dermatomes or disseminated (when it affects two or more dermatomes).
• • Recurrence of HZ is defined as any occurrence of HZ that happens after the initial episode.
• • Active cancer is defined as: diagnosis of local, regionally advanced or metastatic cancer; treatment naïve, receiving oncological therapies or palliative care in the last year.
• Exclusion Criteria:
• • Age under 18 years
• • Absence of evidence of oncological disease: cases classified as complete remission or without evidence of oncological disease (not receiving any kind of oncological treatment for at least one year)